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Abstract. Toxoplasmosis is a cosmopolite disease caused by the protozoan parasite, Toxoplasma gondii. The 
infection may be contracted through the ingestion of raw or undercooked meat or unpasteurised milk, organ 
transplants, blood transfusion, through the placenta in vertical transmission or by direct contact with the 
 faeces of infected felids or even through the ingestion of sporulated oocysts in water or food. In immunocom-
petent individuals, it is generally asymptomatic. However, in patients with various degrees of immunodei-
ciency and in pregnant women, it may cause severe sequelae and can be fatal. In pregnant women, the 
prenatal diagnosis should be made as early as possible, so that therapy may be applied to reduce parasitemia 
and avoid transplacental infection. Despite the high prevalence of infected individuals around the world 
(20-90%), in some European Union countries, such as France and Austria, the average incidence of foetal 
toxoplasmosis was reduced from 40% to 7% by means of speciic programs. In Brazil, seroprevalence may 
vary between 40% and > 80% (South/Southeast-North/Centre-West/Northeast), relecting a signiicant 
 disparity between the public health policies and resources applied in the different regions of the country and 
the human development index (HDI) of each of them. The lack of consistent and periodical data on seropreva-
lence per region makes it dificult to understand the signiicance of this infection and to plan speciic public 
health  policies and strategies. Also important is the fact that Hemotherapy Units are not required to screen 
blood components for toxoplasmosis, not even for immunocompromised patients and pregnant women, or 
organ transplants. Regarding basic and clinical research, toxoplasmosis is not a priority if compared to 
the  allocation of government funds and incentives to other tropical illnesses, such as: Chagas disease, 
Leishmaniasis, Dengue fever. There are also few study groups in Brazil that focus in this basic area, for 
 genomics and  proteomics studies of T. gondii strains–for the design of new methods of diagnosis, antipara-
sitic drugs and a vaccine model for humans and animals. This article reviews the historical, taxonomic and 
epidemiologic aspects, diagnosis methods, treatment and technical-scientiic aspects of Toxoplasma gondii 
and toxoplasmosis in the Brazilian context.
Keywords. Toxoplasmosis, toxoplasma gondii, epidemiology, public health policies.
1 Historical aspects of toxoplasmosis
Toxoplasma gondii was described by Splendore, in 1908 in 
Brazil, affecting lab rabbits, and by Nicole Manceaux, in the 
same year, in a rodent of the Ctenodactylus gondii species, in 
the Tunisian Pasteur Institute (Neves, 1994; Cimerman, 
1999). It was initially named “Leishmania gondii” due to its 
similarity to the Leishmania sp protozoa. The correction of 
the nomenclature took place in 1909 (Nicolle Manceaux, 
1909). The irst description of human infection by this para-
site was made by Jankü, in 1923, with the report of a child 
deceased in Prague (Cimerman, 1999). Torres et al., in 1927, 
described in Rio de Janeiro the presence of microorganisms 
they identiied as Toxoplasma in histological sections of the 
brain, myocardium and skeletal muscle of a newborn de-
ceased 29 days after birth. Wolf Cohen and colleagues, in 
1937, were the irst authors to describe the congenital infec-
tion in man, reporting the occurrence of toxoplasmosis in a 
newborn with encephalitis, meningitis and myelitis.
In the United States, Pinkerton and Weinman, in 1940, and 
Pinkerton and Henderson, in 1941, recorded the occurrence 
of toxoplasmosis in adults, with the isolation of the parasite. 
However, it was only after a serological test was developed, 
Sabin and Feldman’s classic dye test, in 1948, that it became 
possible to demonstrate the high prevalence of the disease 
around the world, contributing immensely to the laboratory 
diagnosis of toxoplasmosis and allowing the execution of 
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epidemiologic studies (Neves, 2000). Finally, Frenkel et al., 
1970, pointed out that oocysts represent the sexual stage of 
the agent. Miller and colleagues, 1972, proved that the only 
mammals capable of supporting the intestinal sexual cycle of 
T. gondii and excrete the oocysts are the felines, both domes-
tic and wild cats. The studies on this disease are abundant and 
the importance of this protozoosis is now clearly character-
ized (Villeneuve, 2003). After a careful review of the existing 
medical literature on toxoplasmosis, we found it could be 
 divided in four stages according to the evolution of the 
knowledge on the matter: the irst characterized by the 
 discovery of the etiologic agent; the second by the descrip-
tion of the infection in man; the third by the introduction of 
serological tests for diagnosis purposes and, lastly, by the 
identiication of the deinitive host.
1.1 Classiication
According to Levine (1977, 1980), Toxoplasma gondii is a 
protozoan parasite of the:
Phylum Protozoa
Subphylum Apicomplexa
Class Sporozoa
Family Sarcocystidae
Subfamily Toxoplasmatinae
Genus Toxoplasma (Nicolle and Manceaux, 1909)
Species T. gondii (Nicolle and Manceaux, 1909)
Since the classiication proposed by the Society of 
Protozoologists (Levine et al., 1980), there were no signii-
cant changes regarding the understanding of the phylogenetic 
lineages of eukaryotes. However, with the advent of molecu-
lar biology, many studies have focused on supra-group and 
infra-group genetic variability. Adl and colleagues, 2005, 
proposed a new system for eukaryote organisms. These au-
thors proposed the organization in six main phylogenetic 
clusters: (1) Opisthokont (animals, fungi, choanolagellata 
and mesomycetozoea); (2) Amoebozoa (amoebae, amoebae-
lagellates); (3) Excavate (Euglenozoa, Heterotrophic 
Flagellates, Diplomonads); (4) Rhizaria (foraminifera); 
(5) Archaeplastida (plants and algae) and (6) Chromalveolate 
(Ciliates, Dinolagellates and Apicomplexans). Toxoplasma 
gondii falls in the Chromalveolate group, Alveolate: 
Apicomplexan: Coccidia subgroups.
2 Introduction
Toxoplasmosis is a very common infection in humans and its 
prevalence ranges from 20 to 90% of the adult world popula-
tion. Seroprevalence varies according to regions, especially 
when related to sanitation conditions and socioeconomic 
 indexes (Hill and Dubey, 2002; Spalding et al. 2003). The 
severity of the infection caused by T. gondii may vary 
 depending of the cellular and humoral immune condition of 
the individual, spanning from very mild symptoms (similar to 
lu) or no symptoms at all, to exuberant clinical symptoms. 
The severe clinical forms generally occur in immunocompro-
mised individuals and pregnant women. Immunocompromised 
individuals (AIDS patients, cancer patients, transplant 
 subjects or patients with genetic immunodeiciencies and dia-
betes), may present high levels of morbidity and mortality 
(Ho-Yen, 1992; Israelski and Remington, 1993; Lewden et 
al., 2005; Khurana et al., 2005). When these individuals be-
come infected, the parasite displays tropism with the nervous 
system. The disease is manifested more frequently through 
neurological symtpoms and may be fatal when treatment is 
not administered quickly. Transplacental transmission may 
occur by primary infection during the entire pregnancy 
(Pelloux et al., 2002; Remington et al., 2001). When the in-
fection is contracted during gestation, the parasite may attach 
itself to the placenta and develop there throughout the rest of 
the pregnancy. In a large number of cases it may affect the 
foetus. The severity of the lesions is related to the stage of the 
gestation and the consequences may be more severe the 
younger the foetus, and may result in miscarriage, stillbirth or 
hydrocephalus. If the infection occurs at a later stage it may 
result in eyesight or hearing disorders or mental retardation. 
The immunoenzymatic methods allow the analysis of the 
 humoral immune proile of the pregnant woman and deter-
mine the risk of infection according to the gestational age, 
allowing the inclusion of pregnant women in therapeutic pro-
tocols designed to inhibit parasitemia (Pinon, 2001; 
Remington, 2004). The combination of antiparasitic toxic 
drugs, such as pyrimethamine and spiramycin, does not 
 always prevent contagion nor does it guarantee the total 
 elimination of tachyzoites (Peyron et al., 2001; Binquet, 
2004). Molecular methods, such as qualitative PCR for the 
B1 gene (repeated 35 times in the T. gondii genome), are used 
to assess the eficacy of treatment in clinical samples such as: 
amniotic luid, umbilical cord blood, placenta, acqueous hu-
mour and various tissues infected by T.gondii (Burg et al., 
1989; Grover et al., 1990; Hohfeld et al., 1994; Pelloux et al., 
1996; Jones et al., 2000; Spalding et al., 2002; Remington et 
al., 2004). The persistence of parasites in biological samples 
from pregnant  women undergoing treatment may indicate the 
resistance of the parasite to the drugs, possibly a result of 
genetic differences  between the T. gondii strains isolated 
(Ajzenberg et al., 2002; Dardé et al., 2004; Vaz, 2006; Vaz, 
2010). The molecular characterization of T. gondii strains by 
techniques such as isoenzymatic tests, restriction fragment 
length polymorphism (RFLP-PCR), automated sequencing 
and random ampliication of polymorphic DNA (RAPD) 
shows a correlation between the genotype and virulence of 
the strain isolated, in addition to the correlation of the strains 
and resistance to the drugs used in treatment of the infection 
(Sibley et al., 1992; Dardé et al., 1992; Cristina et al., 1995; 
Guo et al., 1995; Howe et al., 1997; Dardé et al., 2004). The 
clonal lineages identiied by these techniques are of the types 
I, II and III; they are related to the SAG2 gene of T. gondii 
and are found in strains isolated in humans and animals 
(Sibley et al., 1992; Fuentes, 2001; Vaz, 2010). 
Phylogenetically, the type II and III genotypes belong to 
the same group; however, the type II genotype prevails most 
 often in mice and strains maintained in cellular culture. 
The type I genotype is most associated with congenital 
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toxoplasmosis (Fuentes et al., 2001; Ajzenberg et al., 2002; 
Vaz, 2010). In Brazil studies demonstrate the variations in 
the prevalence of toxoplasmosis in the adult immunocom-
petent population and in pregnant women, as well as the 
 relationship and comparison of various diagnostic methods 
( immunological and parasitological), including T. gondii 
DNA detection methods, in various clinical samples. 
However, these studies are isolated and do not  reveal the 
 consistency and periodicity necessary to the planning of pub-
lic health policies with a view to reverting seroprevalence 
indexes strongly associated to the HDI per region, sanitary 
infrastructure. Few Brazilian research groups also publish 
 articles  addressing the relationship between isolated geno-
types, protocol drugs used and the persistence of parasites 
and severity associated with infections during pregnancy 
(Jaquier, 1995; Camargo et al., 1996; Cantos, 2000; Lopez et 
al., 2000; Coppens et al., 2001; Spalding and Amendoeira, 
2003). The probable cause of this situation may be the failure 
to give a higher priority to toxoplasmosis compared to other 
diseases, such as Chagas’ disease, leishmaniasis and Dengue 
fever, all of which receive substantial public funding. 
3 Epidemiology of congenital toxoplasmosis  
 in Brazil 
The prevalence of T. gondii infection may vary greatly from 
country to country, in different regions in the same country, 
and among different population groups of the same region 
(Remington et al. 2001). These differences are related to the 
characteristics of the parasite, such as the level of infection 
potency and peaceful coexistence with the host, the capacity 
to infect thousands of animal species, including aquatic, land 
and winged animals, and the capacity to inhabit various re-
gions of the globe (in lower proportion in very cold areas, 
arid regions and at high altitudes). Other factors that interfere 
with the epidemiology of T. gondii are feeding habits and 
 cultural characteristics. 
The prevalence of toxoplasmosis in pregnant women in 
Brazil varies a great deal. This fact is related to weather, cul-
tural and, especially, socioeconomic differences found in the 
population (Couto et al., 2003; Vaz e Thomaz-Soccol, 2010). 
Recently, Neto and colleagues (2010) conducted an estimate 
of the regional distribution of congenital toxoplasmosis in 
Brazil based on the results of neonatal triage. The results 
pointed to a general prevalence of congenital toxoplasmosis 
of 1/1.613, varying from 1/1547 to 1/495 in different States. 
According to Table 1 of the above mentioned work, the States 
aflicted at highest rates are Pará, Rondônia, Mato Grosso 
and Maranhão. São Paulo, Paraná, Mato Grosso do Sul and 
some northeastern States presented a low prevalence. These 
studies reveal the need for health and education policies that 
target the prevention and control of congenital toxoplasmosis 
in Brazil while respecting the different characteristics of 
each State. 
Some States have public health programs that aim to re-
duce the mortality of women and children during pregnancy 
and birth. One example is the Programa Mãe Curitiba 
[Curitiba Mother Program] developed in the city of Curitiba, 
capital of the State of Paraná. Created in 1999, on International 
Women’s Day, this Program strives to improve the access and 
quality of prenatal, childbirth, postnatal and newborn assis-
tance in maternities and health units. In terms of prevention 
and treatment of maternal and congenital infections the Mãe 
Curitibana program presents an intervention protocol for 
toxoplasmosis. Any cases of suspected Toxoplasmosis are 
submitted to serologic investigation and, depending on the 
results, are considered: 1- Discarded cases (RN with negative 
IgG and IgM); 2- Conirmed cases (child with or without 
clinical manifestation and and/or positive IgM after one week 
of life, persistently high or rising IgG, presence of T. gondii 
in placental tissue); 3- Cases under investigation (children 
with decreasing IgG and negative IgM at 30 days of life are 
followed up until the serology is negative). 
Brazil has a prenatal program, implemented by the Ministry 
of Health, that includes the clinical-laboratorial diagnosis of 
pregnant women and children exposed to T. gondii risk, avail-
able for all users who seek medical assistance. However, 
there are many dificulties related to the technical and opera-
tional parts, as well as laboratory diagnosis interpretation 
problems. Thus, by knowing the prevalence of pregnant 
women susceptible to toxoplasmosis in various Brazilian 
states and by considering the risk factors in each region, it is 
possible to implement effective control strategies. 
4 Toxoplasmosis–treatment
Despite the importance of toxoplasmosis, there are still few 
effective treatments for this disease, their main goal being the 
reduction of the parasite replication rate so as to avoid more 
extensive damage to the organs involved. It is therefore clear 
that continuous drug therapy is essential to guarantee the 
 prevention of severe complications. The ideal drugs for the 
treatment of toxoplasmosis should be effective, easily obtai-
ned at affordable cost and have no toxicity or hypersensitivity 
reactions. In addition, they cannot pose risks of teratology or 
malformation, allowing their use in pregnant women, and 
should be available in parenteral presentations for patients 
unable to ingest the medication. In addition, they need to be 
effective against all strains of T. gondii, be capable of killing 
tachyzoites and have a high ocular and cerebral penetration 
(Mui, et al., 2008). However, many of these ideal character-
istics are not existent, which compromises the treatment of 
the disease. Since the beginning of the nineties, the standard 
treatment remains unaltered, focusing only on the metabo-
lism of the parasite’s nucleotides. 
The therapy consists of a synergic combination of pyri-
methamine and sulfadiazine, drugs that cause the blockage of 
the synthesis and reduction of the folic acid levels in tachy-
zoites through the inhibition of dihydrofolate reductase and 
 dihydropteroate synthetase, respectively (Martins-Duarte, et 
al., 2009; Boothroyd, 2009). However, the effectiveness of 
this therapy is limited, with approximately 50% of all pa-
tients not responding to treatment (Safarjalani, et al., 2010). 
Moreover, the drugs used only act on the tachyzoites, not af-
fecting the tissue cysts and thus allowing resurgence of the 
disease after treatment is over (Martins-Duarte, et al., 2011). 
We also verify that prolonged exposure to the medication re-
gime currently in use is often associated with various adverse 
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Table 1. Prevalence of congenital toxoplasmosis in each State of Brazil based on a screening of newborns that went through 
triage in the period from September 1995 to July 2009.
STATE Total population 
per State
Number of 
samples
Number of 
positives
Number of newborns 
tested for each 
positive case
Number of positives 
per each 10,000 new-
borns tested
Pará (PA) 7,065,573 14,835 30 495 20
Rondônia (RO) 1,453,756 2,021 4 505 20
Mato Grosso (MT) 2,854,652 9,875 19 520 19
Maranhão (MA) 6,118,995 4,033 6 672 15
Espírito Santo (ES) 3,351,669 4,158 6 693 14
Sergipe (SE) 1,939,426 829 1 829 12
Santa Catarina (SC) 5,866,252 20,517 21 977 10
Bahia (BA) 14,080,654 22,659 22 1,030 10
Roraima (RR) 395,725 2,124 2 1,062 9
Piauí (PI) 3,032,421 6,409 6 1,068 9
Amapá (AP) 587,311 1,086 1 1,086 9
Tocantins (TO) 1,243,627 1,109 1 1,109 9
Rio Grande do Sul (RS) 10,582,840 280,962 200 1,405 7
Goiás (GO) 5,647,035 14,804 10 1,480 7
Minas Gerais (MS) 19,273,506 61,661 38 1,623 6
Ceará (CE) 8,185,286 20,788 11 1,890 5
Distrito Federal (DF) 2,455,903 11,420 6 1,903 5
Pernambuco (PE) 8,485,386 64,915 28 2,318 4
Paraíba (PB) 3,641,395 26,264 11 2,388 4
Paraná (PR) 10,284,503 32,318 12 2,693 4
Rio de Janeiro (RJ) 15,420,375 65,585 23 2,852 4
Alagoas (AL) 3,037,103 18,105 6 3,018 3
São Paulo (SP) 39,827,570 94,712 29 3,266 3
Rio Grande do Norte (RN) 3,013,740 5,442 1 5,442 2
Mato Grosso do Sul (MG) 2,265,274 10,894 2 5,447 2
Amazonas (AM) 3,221,939 2,402 0 – –
Acre (AC) 655,387 237 0 – –
Total 183,987,303 800,164 496 1,613 6
Source: Neto et al., 2010.
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reactions, especially in AIDS patients, which include sup-
pression of bone marrow and cytopenia caused by pyrimeth-
amine (Martins-Duarte, et al., 2010) and hypersensitivity 
 reactions to sulfadiazine in the form of skin allergies 
(Maubon, et al., 2010), leucopoenia, thrombocytopenia and 
fever (Jiang, et al., 2008) and also kidney stones, hepatotox-
icities and nephrotoxicities (Mui, et al., 2005). In general, 
folinic acid is added to the treatments to reduce the risk of 
bone marrow suppression (Montoya and Liesenfeld, 2004). 
Other limitations to this therapy include low tolerance, the 
large number of tablets involved in treatment, the unavail-
ability of the drugs in some countries, the high cost of the 
drugs, and the absence of an intravenous presentation for 
these compounds (Béraud, et al., 2009). Taking into account 
all these dificulties, some alternative therapies were devel-
oped and some drug combinations are available to replace 
the classical therapeutic model. In this context, an alternative 
therapy is the combination of clindamycin and pyrime-
thamine, which has an eficacy similar to that of the combi-
nation with sulfadiazine, and which is also associated with 
 various side effects (Martins-Duarte, et al., 2010). 
Antibiotics such as co-trimoxazole and clindamycin have 
been used as a second treatment option (Fung and 
Kirschenbaum, 1996) in addition to other drugs such as 
 esperamicin and atovaquone, used with limited success, 
 particularly in the long-term treatment of toxoplasmosis pa-
tients (Safarjalani, et al., 2008). Other drugs, such as dap-
sone, trimethoprim, pentamidine and azithromycin, have 
also displayed anti-T. gondii activity and have thus been used 
despite their side effects (Jiang, et al., 2008). In light of this 
scenario, we see that the search for new drugs for the treat-
ment of toxoplasmosis is extremely important, since the 
therapeutic arsenal available continues to be defective. In the 
last few years, a new therapeutic proposal using co-trimoxa-
zole has shown potential and proven more effective in the 
treatment and prophylaxis of encephalitis, lymphadenitis 
and eye infections caused by T. gondii (Alavi and Alavi, 
2010). Co-trimoxazole (trimethoprim/sulfamethoxazole) is 
an affordable medicine, widely available in developing coun-
tries, exists in the parenteral form and has a high diffusion 
rate throughout the central nervous system, in addition to 
being better tolerated than the classic therapy with pyrimeth-
amine/sulfadiazine (Béraud, et al., 2009). In Brazil we ind 
that the classical drug treatment still remains unaltered, 
 using the sulfadiazine, pyrimethamine and folinic acid com-
bination, alternating with esperamicin, both in paediatric 
patients and in pregnant women (Higa, et al., 2010; Sáfadi, et 
al., 2003). The therapeutic models used vary according to the 
initial levels of IgM; in general, seropositive women (IgM+/
IgG-) are treated more often (Castilho-Pelloso, et al., 2007). 
However, recent studies using genetic characterization have 
shown that the T. gondii strains found in certain areas of 
Brazil are atypical, mostly corresponding to subtype I and 
not to the subtypes II and III seen in Europe and in many 
English-speaking countries in the Northern Hemisphere 
(Vaz, 2006; Vaz, 2010; Vaz e Thomaz-Soccol, 2010). 
Furthermore, they were found to be genetically polymorphic 
and associated with more severe manifestations of disease in 
humans (Mui, et al., 2008). Therefore, additional studies 
involving the parasite’s proteomics and functional genomics 
are necessary for the development of new drugs, a viable and 
safe vaccine, and more speciic  diagnosis methods.
5 Discussion
Until now, Brazil does not have a consistent oficial program 
for congenital toxoplasmosis (CT) at a national level to  assess 
and follow-up pregnant women in prenatal triage throughout 
the pregnancy period, provide childbirth assistance and post-
partum follow-up to the mother and newborn; only isolated 
cases exist, like the Programa Mãe Curitiba [Curitiba’s 
Mother Program], in the State of Paraná. Recently, the 
Government of the State of São Paulo implemented the 
Programa Mãe Paulistana [São Paulo’s Mother Program] for 
pregnant women in the city of São Paulo that follows the 
model of Mãe Curitibana, which this year celebrates its 
12th anniversary and which achieved a reduction of the sero-
prevalence associated with CT from 53% (2004-2006 data) to 
< 45% (recent data). The Federal Government and the 
Ministry of Health intend to replicate these success models in 
other capitals and, in the medium term, in the public network 
in all the country’s States. Even so, for the new public health 
policies to be enforced in a more effective manner, it would 
be necessary to collect seroprevalence data in all regions of 
the country in a continuous manner, month after month, year 
after year, to allow the observation of the development of 
toxoplasmosis in the country as a whole and to deine speciic 
strategies for regions with different socioeconomic aspects, 
sanitary infrastructures and HDI. Generally speaking, we do 
not know (exactly) the number of pregnant women in the 
country susceptible of seroconversion potential throughout 
gestation and, even in regards to the registered miscarriages, 
what percentage is associated with toxoplasmosis. In terms of 
scientiic research in the basic and clinical area, the country 
has isolated groups with speciic research lines per area. In 
the area of basic research and technological innovation, the 
situation is the same. However, in the Conference of the 
100th anniversary of Toxoplasma gondii–TOXO-100 (Búzios-
RJ–September 2008), promoted by the Brazilian, French, 
European and North American Parasitology Societies, it was 
found that the Brazilian and South American T. gondii strains 
were very different from the North American and European 
strains, where in Brazil the most prevailing strain associated 
with CT is type I, with more aggressive characteristics when 
compared to the Northern hemisphere strains. Another aspect 
not well publicized, not only in Brazil but around the world in 
general, is the matter of screening blood for toxoplasmosis, at 
least for immunocompromised patients and in transplant 
 patients (Vaz et al., 2008). There is no law in Brazil that 
 requires hemotherapy centres to triage blood components for 
that purpose. This fact may facilitate the infection of patients 
whose immunity is frail. There are no national studies that 
demonstrate this fact. For the deinition of the prevalence of 
lineages of T. gondii strains in Brazil, it would be necessary 
to collect clinical samples from the various regions of the 
country for molecular characterization and, also, to ascertain 
if there are intragenotypic variations. These data would be 
very valuable for the development of new diagnosis tools, 
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since most methods used in the national territory come from 
European countries and from North America and are created 
from regional strains, and also to allow the development of 
new drugs, more effective that those currently used which are 
not effective in many clinical situations. In addition, there 
would be the possibility of new vaccine models, both for hu-
mans and animals. Generally speaking, the understanding at 
various levels of this parasite infection and of the speciic 
Brazilian parasite opens several revaluation perspectives for 
our health system, for appropriate funding of the research 
groups and for their coverage of the entire national territory. 
The wider understanding of this infection would allow us to 
know the impact it has on human and animal health and 
which speciic measures could be implemented in terms of 
public health so as to revert the current scenario.
References
Adl, S. M.; Simpson, A. G. B.; Farmer, M. A.; Andersen, R. A.; 
Anderson, O. R.; Barta, J. R.; Bowser, S. S.; Brugerolle, G.; 
Fensome, R. A.; Fredericq, S.; James, T. Y.; Karpov, S.; 
Krugens, P.; Krug, J.; Lane, C. E.; Lewis, L. A.; Lodge, J.; Lynn, 
D. H.; Mann, D. G.; McCourt, R. M.; Mendoza, L.; Moestrup, O.; 
Mozley-Standridge, S. E.; Nerad, T. A.; Shearer, C. A.; Smirnov, 
A. V.; Spiegel, F. W. and Taylor, M. F. J. R. The New Higher Level 
Classiication of Eukaryotes with Emphasis on the Taxonomy of 
Protists. J Eukaryot Microbiol. v. 52, n. 5, p. 399-451, 2005. 
Ajzenberg, D.; Cogné, N.; Paris, L.; Bessières, M. H.; Thulliez, P.; 
Filisetti, D.; Pelloux, H.; Marty P.; Dardé, M. L. Genotype of 
86 Toxoplasma gondii Isolates Associated with Human 
Congenital Toxoplasmosis, and Correlation with Clinical 
Findings. J Infect Dis. v. 186, n. 5, p. 684-689, 2002. 
Binquet, C.; Wallon, M.; Metral, P.; Gadreau, M.; Quantin, C.; 
Peyron, F. Toxoplasmosis seroconversion in pregnant women. 
The differing attitudes in France. Presse Med. v. 33, n. 12, 
p. 775-779, 2004. 
Boothroyd, J. C. (2009) Toxoplasma gondii: 25 years and 25 major 
advances for the Field. Int J Parasitol. July 1; 39(8): 935-946.
Burg, J. l.; Grover, G. M.; Pouletty, P. et al. Direct and sensitive 
 detection of a pathogenic protozoan, Toxoplasma gondii by 
polymerase chain reaction. J Clin Microbiol. v. 8, n. 27, p. 1787-
1792, 1989. 
Camargo, M. E. Toxoplasmosis. In: Ferreira A. W., Ávila S. L. M. 
(eds) Diagnóstico laboratorial das principais doenças infecciosas 
e auto-imunes, Ed Guanabara Koogan, Rio de Janeiro, p. 165-
174, 1996.
Cantos, G. A. A.; Prando, M. D.; Siqueira, M. V.; Teixeira, R. M. 
Toxoplasmosis:ocorrência de anticorpos anti-Toxoplasma gondii 
e diagnóstico. Rev da AssocMed Bras. v. 46, n. 4, p. 335-341, 
2000.
Castilho-Pelloso, M.; Falavigna, D. L. M; Falavigna-Guilherme, 
A. L. (2007) Suspected acute toxoplasmosis in pregnant women. 
Rev Saúde Pública., 41(1):27-34. 
Cimerman B. & Cimerman S., Parasitologia Humana e seus 
Fundamentos Gerais, Ed. Atheneu, São Paulo, 375 p, 1999. 
Coppens, I.; Joiner, K. A. Parasite-host cell interactions in toxoplas-
mosis: new avenues for intervention? Expert Rev Mol Med. 
Cambridge University Press (CUP), v. 15, 2001.
Cristina, N.; Dardé, M. L.; Boudin, C.; Tavernier, G.; Pestre-
Alexandre, M. And Ambroise-Thomas, P. A DNA ingerprinting 
method for individual characterization of Toxoplasma gondii 
strains: combination with isoenzymatic characters for determi-
nation of linkage groups. Parasitol. v. 81, n. 1, p. 32-33, 1995.
Couto, J. F. C.; Melo, R. N.; Rodrigues, M. V.; LEITE, J. M. (2003) 
Diagnóstico pré-natal e tratamento da toxoplasmosis na gestação. 
Femina, v. 31, n. 1, p. 85-90. 
Dardé, M. L., Bouteille, and M. Pestre-Alexandre. Isoenzyme 
 analysis of 35 Toxoplasma gondii isolates and the biological and 
epidemiological implications. J Parasitol. v. 78, n. 5, p. 786-794, 
1992.
Dardé M L. Genetic analysis of the diversity in Toxoplasma gondii. 
Ann Ist SuperSanita. v. 40, n. 1, p. 57-63, 2004.
Frenkel, J. K.; Dubey, J. P. & Miller, N. L.(1970). Toxoplasma gon-
dii in cats: Fecalstages identiied as coccidian oocysts. Science. 
v. 167, n. 919, p. 893-896, 1970. 
Fuentes, I.; Rubio, J. M.; Ramirez, C. and Alvar, J. Genotypic 
Characterization of Toxoplasma gondii Strains Associated with 
Human Toxoplasmosis in Spain: Direct Analysis from Clinical 
Samples. J Clin Microbiol. v. 39, n. 4, p. 1566-1570, 2001. 
Grover, C. M.; Thulliez, P.; Remington, J. S.; Boothroyd, J. C.. 
Rapid prenatal diagnosis of congenital Toxoplasma infection by 
using polymerase chain reaction and amniotic luid. J Clin 
Microbiol. v. 28, n. 10, p. 2297-2301, 1990. 
Guillaume, B.; Sandrine, P. F; Adeline, F.; Sylvie, A.; Bernard, L.; 
Didier, S.; Cabié. A. (2009) Cotrimoxazole for Treatment of 
Cerebral Toxoplasmosis. Am. J. Trop. Med. Hyg., 80(4), 
p. 583-587. 
Higa, L. T.; Araújo, L. T.; Tsuneto, L.; Castilho-Pelloso, M.; Garcia, 
J. L.; Santana, R. G.; Falavigna-Guilherme, A. L. (2010) A pro-
spective study of Toxoplasma-positive pregnant women in 
southern Brazil: a health alert. Transactions of the Royal Society 
of Tropical Medicine and Hygiene 104, p.400-405. 
Hohlfeld, P.; Daffos, F.; Costa, J. M.; Thulliez, P.; Forestier, F.; 
Vidaud, M. Prenatal diagnosis of congenital toxoplasmosis with 
a polymerase chain reaction test on amniotic luid. N Engl J 
Med. v. 331, n. 11, p. 695-699, 1994.
Howe, D. K.; Sibley, L. D. Toxoplasma gondii comprises three clon-
al lineages: correlation of parasite genotype with human disease. 
J Infect Dis. v. 172, n. 6, p. 1561-1566, 1995.
Hill, D., Dubey, J. P. Toxoplasma gondii: transmission, diagnosis 
and prevention. Clin Microbiol Infec. v. 8, p. 634-640, 2002.
Horatio, B. F.; Kirschenbaum, H. A. (1996) Treatment Regimens for 
Patients with Toxoplasmic Encephalitis. Clinical Therapeutics. 
v. 18, n. 6, p.1037-1056. 
Ho-Yen, D. O.; Joss A. W.; Balfou,r A. H.; Smyth, E. T.; Baird, D.; 
Chatterton, J. M. Use of the polymerase chain reaction to detect 
Toxoplasma gondii in human blood samples. J Clin Pathol. v. 45, 
n. 10, p. 910-913, 1992.
Israelski, D. M. & Remington, J. S. Toxoplasmosis in patients with 
cancer. Clin Infect Dis. 1993, v. 17, n. 2, p. 423-435, 1993. 
Jacquier, P.; Nadal, D.; Zuber, P.; Eckert, J. The status of infection 
with Toxoplasma gondii in the Swiss population: contribution of 
a seroepidemiologic study from the Zurich canton. Schweiz Med 
Wochenschr Suppl. v. 65, n. 23S-28S, 1995.
Jankü, J. Pathogenes a pathologická anatomie taknazvaného vino-
zeného kolohome zluté skrny v oku normálne velikém a mikroph-
thalmickém s nálezem parazitu v sítnici. Cas Lék Ces. v. 62, 
p. 1021-1027, 1054-1059, 1081-1085, 1111-1115, 1138-1144, 1923.
Jiang, J. H.; Jim, C. M.; Kim, Y. C.;, Kim, H. S.; Park, W. C.; Park, 
H. (2008) Anti-toxoplasmosis Effects of Oleuropein Isolated 
from Fraxinus rhychophylla. Biol. Pharm. Bull. 31(12), p. 2273-
2276. Jones, C. D.; Okhravi, N.; Adamson, P.; Tasker, S. and 
Susan Lightman. Comparison of PCR Detection Methods for 
B1, P30, and 18S rDNA Genes of T. gondii in Aqueous Humor. 
Invest Ophthal & Vis Science. v. 41, n. 3, 2000.
R. S.Vaz et al: Congenital Toxoplasmosis: A Neglected Disease?
7www.factsreports.org
Guo, Z. G. and Johnson, A. M. Genetic characterization of 
Toxoplasma gondii strain by random ampliied polymorphic 
DNA polymerase chain reaction. Parasitol. v. 111, (part 2), 
p. 127-132, 1995. 
Khurana, S.; Dubey, M. L.; Malla N. Association of Parasitic 
Infections and Cancers. Ind J Med Microbiol. v. 23, n. 2, p. 74-
79, 2005.
Levine, N. D. Some corrections of coccidian (Apicomplexa: 
Protozoa) nomenclature. J Parasitol. v. 66, n. 5, p. 830-834, 
1980. 
Lewden, C.; Salmon, D.; Morlat, P.; Bévilacqua, S.; Jougla, E.; 
Bonnet, F.; Héripret, L.; Costagliola, D.; May, T.; Chêne, G. and 
the Mortality 2000 study group. Causes of death among human 
immunodeiciency virus (HIV)-infected adults in the era of 
 potent antiretroviral therapy: emerging role of hepatitis and 
 cancers, persistent role of AIDS. Intl J Epidemiol. v. 34, n. 1, 
p. 121-130, 2005.
Lopez, A, Dietz VJ, Wilson M, Navin TR, Jones J. L. Preventing 
Congenital Toxoplasmosis. M M W R–Recommendations and 
Reports. v. 49, (RR02), p. 57-75, 2000.
Martins-Duarte, E. S.; Jones, S. M.; Gilbert, I. H.; Atella, G. C.; 
Souza, W.; Vommaro, R. C. (2009) Thiolactomycin analogues as 
potential anti-Toxoplasma gondii agents. Parasitology Inter-
national 58, p.411-415.
Martins-Duarte, E. S.; Lemgruber, L.; Souza, W.; Vommaro, R. C. 
(2010) Toxoplasma gondii: Fluconazole and itraconazole acti-
vity against toxoplasmosis in a murine model. Experimental 
Parasitology 124, P. 466-469. 
Martins-Duarte, E. S.; Lemgrubera, L.; Lorente, S. O.; Gros, L.; 
Magaraci, F.; Ian H. Gilbert, Wanderley de Souzaa, Rossiane C. 
Vommaroa. (2011) Evaluation of three novel azasterols against 
Toxoplasma gondii. Veterinary Parasitology 177 p.157-161. 
Maubon, D.; Bougdour, A.; Wong, W.; Brenier-Pinchart, M-P.; Curt, 
A.; Hakimi, M-A.; Pelloux, M. (2010) Activity of the histone 
deacetylase inhibitor fr235222 on Toxoplasma gondii: inhibition 
of stage conversion of the parasite cyst form and study of new 
Derivative Compounds Antimicrobial Agents And Chemothe-
rapy, p. 4843-4850. 
Miller, N. L.; Frenkel, J. K.; Dubey, J. P. Oral infections with 
Toxoplasma cysts and oocysts in felines, other mammals, and 
in birds. J Parasitol. v. 58, n. 5, p. 928-937, 1972.
Montoya, J. G.; Liesenfeld, O. (2004) Toxoplasmosis. Lancet, 
v. 363: p.1965-76.
Mui, E. J.; Jacobus, D.; Milhous, W. K.; Schiehser, G.; Hsu, H.; 
Roberts, C’W.; Kirisits, M. J.; McLeod, R. (2005) Triazine 
Inhibits Toxoplasma gondii Tachyzoites In Vitro and In Vivo. 
Antimicrobial agents and chemotherapy, p. 3463-3467.
Mui, E. J.; Schiehser, G. A.; Milhous, W. K.; Hsu, H.; Roberts, 
C. W.; Kirisits, M.; Muench, S.; Rice, D.; Dubey, J. P.; Joseph, 
W.; Fowble, Pradipsinh K. Rathod, Sherry F. Queener, Susan R. 
Liu, David P. Jacobus, Rima McLeod. (2008) Novel Triazine 
JPC-2067-B Inhibits Toxoplasma gondii In Vitro and In Vivo. 
Public Library of Science Neglected Tropical Diseases, v. 2, 
Issue 3, p. 1-13.
Neto, C.N.; Amorim, F.; Lago, E. G. (2010) Estimation of the re-
gional distribution of congenital toxoplasmosis in Brazil from 
the results of neonatal screening. Sci. Med, v. 20, n.1, p. 64-70. 
Neves, J. M.; Nascimento, L. B.; Ramos, J. G. L.; Martins-Costa, 
S. H. Toxoplasmosis na gestação. Rev Bras Ginecol Obstet. 
v. 16, n. 6, p. 197-202, 1994.
Neves, D. P.; Melo, A. L.; Genaro, O. & Linardi, P. M. Parasitologia 
Humana. 10a. Ed.: Ed. Atheneu, São Paulo, p. 428, 2000.
Nicole, C.; Manceaux, L. Sur une infection a corps de leishman (ou 
organismevoisins) du gondii: C. R. Acad Sci. n. 147, p. 763-766, 
1908.
Nicole C, Manceaux L. Sur un protozoaire nouveau du gondii. Acad 
Sci. n. 147, p.763-766, 1909. Pelloux, H.; Fricker-Hidalgo, H.; 
Pons, J. C.; Bost-Brut, C.; Brenier-Pinchart, M. P.; Jouk, P. S.; 
Ambroise-Thomas, P. Congenital toxoplasmosis: prevention in 
the pregnant woman and management of the neonate. Arch 
Pediatr. v. 9, n. 2, p. 206-212, 2002. 
Pelloux, H.; Weiss J.; Simon, J.; Muet, F.; Fricker-Hidalgo, H.; 
Goultier-Fleuret, A.; Ambroise Thomas, P. A new set of primers 
for the detection of Toxoplasma gondii in amniotic luid using 
polymerase chain reaction. FEMS Microbiol Lett. v. 138, n.1, 
p. 11-15, 1996
Peyron, F.; Wallon, M. Options for the pharmacotherapy of toxo-
plasmosis Turing pregnancy. Expert Opin Pharmacother. v. 2, 
n. 8, p. 1269-1274, 2001.
Pinkerton, H.; Weinman, D. Toxoplasmosis infection in man. Arch 
Pathol. v. 30, p. 374-392, 1940.
Pinkerton, H.; Henderson, R. G. Adult toxoplasmosis. A previously 
unrecognized disease entry simulating the typhus-spotted fever 
group. J Am Assoc. 1941, 116:807-814. Apud: Amato Neto, 
V. Medeiros, E. A. S., Levi, G. C., Duarte, M. I. S. Toxoplasmosis. 
4a. Ed. São Paulo, Savier, p. 154, 1995. 
Pinon, J. M.; Dumon, H.; Chemla, C.; Franck, J.; Petersen, E.; 
Lebech, M.; Zufferey, J.; Bessieres, M.-H.; Marty, P.; Holliman, 
R.; Johnson, J.; Luyasu, V.; Lecolier, B.; Guy, E.; Joynson, 
D. H. M. ; Decoster, A. ; Enders, G. ; Pelloux, H. and Candoli, 
E. Strategy for Diagnosis of Congenital Toxoplasmosis: 
Evaluationof Methods Comparing Mothers and Newborns and 
Standard Methods for Postnatal Detection of Immunoglobulin 
G, M, and A Antibodies. J Clin Microb. v. 39, n. 6, p. 2267-2271, 
2001.
Remington, S. J; McLeod, R.; Thulliez, P.; Desmonts, G. (2001) 
Toxoplasmosis. In: 
Remigton, J. S.; Klein, j.o editors. Infectious diseases of the fetus 
and newborn infant. Philadelphia, WB Sauders Company, 
p. 205-346. 
Remington, J. S.; Thulliez, P.; Montoya, J. G. Recent Developments 
for Diagnosis of Toxoplasmosis. J Clin Microbiol. v. 42, n. 3, 
p. 941-945, 2004.
Sabin, A.B.; Feldman, H.A. Dyes as microchemical Indications of 
a new immunity phenomenon affecting a protozoan parasite 
(Toxoplasma). Science. v. 108, p. 660-663, 1948.
Sáfadi, M. A. P.; Berezin, E. N.; Farhat, C. K.; Carvalho, E. S. 
(2003) Clinical Presentation and Follow Up of Children With 
Congenital Toxoplasmosis in Brazil. The Brazilian Journal of 
Infectious Diseases, 7(5), p. 325-331.
Safarjalania, O. N. A.; Reem H. Raisa, Young Ah Kimb, Chung K. 
Chub, Fardos N. M. Naguiba, and Mahmoud H. el Kounia. 
(2008) 7-Deaza-6-benzylthioinosine analogues as subversive 
substrate of Toxoplasma gondii adenosine kinase: Activities and 
selective toxicities. Biochem Pharmacol. v. 76, 958-966.
Safarjalani, O. N. A.; Reem H. Rais, Young Ah Kim, Chung K. Chu, 
Fardos N. M. Naguib, Mahmoud H. el Kouni. (2010) Carbocyclic 
6-benzylthioinosine analogues as subversive substrates of 
T. gondii adenosine kinase: Biological activities and selective 
toxicities.Biochemical Pharmacology v. 80, p. 955-963. 
Seyed, M.; Leila A. (2010) Treatment of toxoplasmic lymphadenitis 
with co-trimoxazole. International Journal of Infectious Diseases, 
v.14, p.67-69. 
R. S.Vaz et al: Congenital Toxoplasmosis: A Neglected Disease?
8 Field Actions Science Reports
Sibley1, L. D.; LeBlanc, A. J.; Pferfferkorn, E. R.; Boothroyd, J. C. 
Generation of a restriction fragment length polymorphism link-
age map for Toxoplasma gondii. Genetics. v. 132, n. 4, p. 1003-
1015, 1992.
Sibley2, L. D. and Boothroyd, J. C. Virulent strains of Toxoplasma 
gondii comprise a single clonal lineage. Nature. v. 359, p. 82-85, 
1992. 
Spalding, S. M.; Amendoeira, M. R. R.; Coelho, J. M. C.; Angel, 
S. O. Otimização da reação em Cadeia da Polimerase para 
Detecção de Toxoplasma gondii em Sangue Venoso e Placenta 
de Gestantes.J Bras Patol Med Lab. v. 38, n. 2, p. 105-110, 2002.
Spalding, S. M.; Amendoeira, M. R. R.; Ribeiro, L. C.; Silveira, C.; 
Garcia, A. P. E Camillo-Coura, L. Estudo prospectivo de gestan-
tes e seus bebês com risco de transmissão de congenital toxo-
plasmosis em município do Rio Grande do Sul. Rev da Soc Bras 
de Med Trop. v. 36, n. 4, p. 483-491, 2003. 
Torres, C. M. Sur une nouvelle maladie de l’homme, charactérisée 
par la présence d’une parasite intracellulaire, très proche de 
Toxoplasma et de l’Encephalitozoon, dans le tissu musculaire 
cardique, les muscles du squelette, le tissu cellulair sourcutane et 
le tissu nerveux. C R Soc Biol. v. 97, p. 1778-1781, 1927. 
Vaz, R. S. Diagnóstico sorológico, isolamento e caracterização 
 molecular de Toxoplasma gondii (Nicole & Manceaux, 1909) em 
mulheres gestantes atendidas pelo serviço público na cidade 
de Curitiba. (SERODIAGNOSTIC, ISOLATION AND MOLE-
CULAR CHARACTERIZATION OF Toxoplasma gondii IN 
PREGNANT WOMEN ATTENDED BY PUBLIC HEALTH 
SERVICES IN THE CITY OF CURITIBA. http://www.ppgbiotec.
ufpr.br/tes_teses.php Tese: Doutorado–Universidade Federal 
do Paraná. Setor Tecnológico. Pósgraduação em Processos 
Biotecnológicos. 2006
Vaz et al. Technical evaluation of serological screening tests for 
anti-Toxoplasma gondii Antibodies to prevent unnecessary 
transfusion risks. Rev Bras Hematol Hemoter. 2008; v. 30, 
277-280
Vaz, R. S. Relevance of genotype-I in congenital toxoplasmosis in 
Brazil: Analysis of Toxoplasma gondii surface antigen 2 gene 
(SAG2). 14th Internacional Congreso of Immunology–ICI-2010 
KOBE JAPAN. 2010ª-A-3905–ICI.
Vaz et al., 2010. Serological prevalence of Toxoplasma gondii anti-
bodies in pregnant womenFrom Southern Brazil. Parasitol Res 
(2010) 106:661-665.
Villeneuve, A. Les zoonoses parasitoires. L’infection chez les 
 animaux et chez les hommes. Les Presses de L’Université de 
Montréal, Québec, 499 p, 2003.
Wolf, A.; Cowen, D. Granulomatous encephalomyelitis due to an 
encephalitozoon (encephalitozoic encephalomyelitis). A new 
protozoan disease of man. Bull Neurol Inst NY. v. 6, p. 306-371, 
1937.
